Holen Sie sich die Stockscreener-App
1.82
0.00%
0.00
Handel nachbörslich:
1.81
-0.01
-0.55%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.82
Offen:
$1.85
24-Stunden-Volumen:
2.32M
Relative Volume:
0.78
Marktkapitalisierung:
$809.82M
Einnahmen:
$69.64M
Nettoeinkommen (Verlust:
$-26.09M
KGV:
-25.45
EPS:
-0.0715
Netto-Cashflow:
$-38.80M
1W Leistung:
+1.39%
1M Leistung:
-18.75%
6M Leistung:
+14.47%
1J Leistung:
+31.88%
1-Tages-Spanne:
$1.80
$1.87
1-Wochen-Bereich:
$1.80
$2.05
52-Wochen-Spanne:
$1.10
$2.68
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.82 | 798.70M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals upgraded to Buy with ke... - Pluang
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More - Seeking Alpha
Lexicon Pharmaceuticals stock reaches a key HCM milestone - AD HOC NEWS
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - uk.finance.yahoo.com
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - Yahoo Finance
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - The Motley Fool
Cantor Fitzgerald Initiates Overweight on Lexicon Pharmaceuticals (LXRX) Ahead of Phase 3 Inpefa Data - GuruFocus
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy - Seeking Alpha
Why is Lexicon Pharmaceuticals stock surging today? By Investing.com - Investing.com Australia
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Investing.com Nigeria
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight By Investing.com - Investing.com Canada
LXRX Initiated Coverage by Cantor Fitzgerald -- Rating Set at Ov - GuruFocus
Cantor Fitzgerald initiates coverage of Lexicon Pharmaceuticals with Overweight rating, $8 price target - TradingView
Cantor Fitzgerald Initiates Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Announces Target Price $8 - Moomoo
Lexicon Pharmaceuticals stock trades near its yearly low - AD HOC NEWS
Diabetic Peripheral Neuropathy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Helixmith, Lexicon Pharma, Glenmark Pharma, Praetego - Barchart.com
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data - Yahoo Finance
Lexicon Pharmaceuticals stock holds steady as investors eye recent results - AD HOC NEWS
Lexicon Pharmaceuticals at H.C. Wainwright conference: catalysts ahead By Investing.com - Investing.com Australia
Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - webull.com
Lexicon Pharmaceuticals Inc. (LXRX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens - Investing.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us
Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
LXRX|Lexicon Pharmaceuticals Inc|Price:2.240|Chg%:-0.020 - TradingKey
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences - The Manila Times
Three New York investor conferences will hear from Lexicon - Stock Titan
Lexicon Pharmaceuticals (LXRX) Posts Positive Heart Failure Tria - GuruFocus
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - Yahoo Finance
Lexicon Pharmaceuticals Inc. (LXRX) Peer Comparison – Compare with Others - Value Research
Lexicon Pharmaceuticals Inc. (LXRX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Lexicon (LXRX) Results at a Glance: EPS Misses Its Estimate in the Reported Period; Post-Earnings: The Market Price Advances 0.87% at the CloseNegative Surprise Momentum - vinanet.vn
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Advances Obesity Drug Trial, Faces Valuation Challenges - GuruFocus
Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 - marketscreener.com
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
LEXICON PHARMACEUTICALS, INC. SEC Filing (Aug 17, 2026) - Stock Titan
Lexicon Pharmaceuticals (LXRX) Trading Near $2.34: Support and Resistance Define Near-Term RangeGamma Squeeze - vinanet.vn
Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st
Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.01 (As of Aug. 15, 2026) - GuruFocus
Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
126,122 |
| SOBECKI CHRISTOPHER J | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
293,177 |
| Cheung Ivan | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
89,312 |
| BARKER SAM L | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
213,771 |
| Amouyal Philippe | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
374,486 |
| DEBBANE RAYMOND | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
1,995,498 |
| Artal Participations S.a r.l. | Director |
Apr 30 '26 |
Option Exercise |
0.00 |
20,421,735 |
0 |
175,156,062 |
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):